FARN:LON
Faron Pharmaceuticals Oy
GBX 42.55
arrow_downward
-1.05%(-0.45) 1H
8 Mei, 4:30:00 PTG GMT+1 · GBX
search
Semua simbol
1H
5H
1B
6B
TSS
1T
5T
MAKS
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk FARN...
Buka
GBX 42.00
Tinggi
GBX 44.00
Rendah
GBX 40.55
Permodalan Pasaran
83.72J
Purata volum
119.93K
Volum
50.37K
tgi 52 mgu
GBX 248.89
rdh 52 mgu
GBX 38.00
EPS
-GBX 0.19
Syer tertunggak
31.03J
Bilangan pekerja
33
Cerita berita
Daripada sumber merentas web
MarketBeat
·
1 jam lalu
RealReal (NASDAQ:REAL) Issues Earnings Results
MarketBeat
·
1 jam lalu
Runway Growth Finance (NASDAQ:RWAY) Posts Earnings Results
Simply Wall Street
·
1 jam lalu
ACM Research (ACMR) Margin Compression To 9.5% Tests Bullish Growth Narrative
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Perihal Faron Pharmaceuticals Oy
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut